Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
505.75
-10.69 (-2.07%)
At close: Aug 14, 2026, 4:00 PM EDT
504.21
-1.54 (-0.30%)
After-hours: Aug 14, 2026, 7:58 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $563.12. The average 1-year stock price forecast is 11.34% higher than the current stock price, while the lowest is $350 (-30.80%) and the highest is $672 (+32.87%).
Price Target: $563.12 (+11.34%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 22 | 21 | 21 | 21 | 19 | 19 |
| Buy | 5 | 5 | 6 | 6 | 4 | 4 |
| Hold | 4 | 5 | 5 | 4 | 4 | 5 |
| Sell | 1 | 0 | 0 | 1 | 1 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 33 | 32 | 33 | 33 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $570 | Buy | Maintains | $570 | +12.70% | Aug 12, 2026 |
| Jefferies | Jefferies | Buy Maintains $610 → $633 | Buy | Maintains | $610 → $633 | +25.16% | Aug 11, 2026 |
| Bernstein | Bernstein | Buy Maintains $608 | Buy | Maintains | $608 | +20.22% | Aug 11, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $558 | Buy | Maintains | $558 | +10.33% | Aug 11, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 11, 2026 |
Financial Forecast
Revenue This Year
13.19B
from 12.00B
Increased by 9.90%
Revenue Next Year
14.58B
from 13.19B
Increased by 10.58%
EPS This Year
19.05
from 18.40
Increased by 3.54%
EPS Next Year
21.80
from 19.05
Increased by 14.43%
EPS and Forward PE are based on non-GAAP adjusted numbers.